2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
It is a portion of a protein that occurs naturally in human gastric juice, commonly referred to as Body Protection Compound (BPC). Native BPC helps maintain gastrointestinal integrity under normal physiological conditions.
BPC-157 is stable and soluble in water. As a synthetic peptide, BPC-157 is not produced endogenously in this exact form but is designed to replicate a biologically active fragment of the parent protein found in gastric secretions [1].
The peptide has been the subject of extensive preclinical research, particularly in the context of cellular proliferation, angiogenesis, and tissue repair mechanisms. BPC-157 has been studied in animal and in vitro models as a tool for investigating pathways associated with:
All research involving BPC-157 remains within the domain of experimental studies, and it is not approved for human therapeutic use.
BPC-157 has been extensively studied in preclinical models for its modulatory effects on inflammation, particularly in relation to tissue injury and repair processes [1].
In various rodent studies, administration of BPC-157 reduced markers of inflammation in models of gastrointestinal, musculoskeletal, and neural injury. By modulating inflammation, rat studies suggest that various BPC variants modulate pain, while BPC-157 predominantly reduces acute pain in incisional and formalin-induced pain [2]. In a rat model of allodynia, it also reduced pain by protecting nerve integrity from capsaicin [3].
BPC may also modulate the nitric oxide (NO) system. It counteracts both excessive and deficient NO activity, supporting endothelial integrity and attenuating leukocyte infiltration in inflamed tissues.
This dual regulation may contribute to its observed ability to balance pro-inflammatory and anti-inflammatory signaling cascades [4].
In experimental colitis models, for example, BPC-157 administration was associated with:
BPC-157 also promotes angiogenesis (blood vessel growth) and stabilizes vascular function at sites of injury. This angiogenic support not only facilitates tissue repair but may also limit secondary inflammation resulting from ischemia and oxidative stress [5].
Research in tendon and ligament injury models similarly highlights reductions in edema and inflammatory cell presence following BPC-157 exposure.
These findings are derived from animal studies, and while promising, they await confirmation in human clinical research to fully understand its therapeutic relevance.
BPC-157 can facilitate regeneration across various tissue types, including:
A key feature identified in these models is BPC-157’s capacity to modulate cellular and immune environments in ways that promote structural integrity and restoration of injured sites.
In rat models of tendon fibroblasts, BPC-157 significantly upregulated growth hormone receptor expression, and enhanced the responsiveness of these cells to endogenous growth hormone [6].
This interaction promotes cell proliferation and tissue regeneration, increasing expression of proliferation markers:
These results suggest a supportive role in tendon repair processes at the molecular level, enhancing the body's natural regenerative mechanisms.
BPC-157 may influence stem cell activity indirectly by optimizing the local microenvironment of injured tissues.
While direct stimulation of stem cell differentiation by BPC-157 has not been definitively proven, its actions on surrounding tissues, blood vessels, and extracellular matrix components are believed to indirectly enhance stem cell-mediated repair processes.
BPC-157 has been extensively studied in preclinical models for its protective and regenerative effects on the gastrointestinal (GI) tract [7].
Research in rat models of ileoileal anastomosis healing, for instance, shows that BPC-157:
BPC-157 reduced adhesion formation and necrosis, while accelerating the resolution of edema and inflammatory infiltrates in treated animals compared to controls.
Additional experimental models of intestinal injury, including those involving perforations, fistulas, or induced colitis, report that BPC-157 administration supported gut integrity by:
The peptide’s influence on nitric oxide pathways and its modulation of endothelial function are proposed mechanisms underlying these benefits.
While clinical trials in humans remain limited, the consistent findings across animal models offer a compelling basis for future investigation into its application in gut health contexts.
Bees are crucial pollinators whose populations are in significant declines. Research suggests that BPC-157 may help to improve bee health and survival. In bees, BPC-157 improves colony strength and enhances certain aspects of immune responses [8]. Supplementation of bee diets with the peptide reduced the infection load of the Nosema ceranae, a one-celled fungal parasite. BPC-157 also attenuates gut damage from N. ceranae infections [8]. Overall, BPC-157 may be beneficial in beekeeping.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). BPC-157 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
BPC-157, also called Bpc-157, is a synthetic pentadecapeptide derived from gastric proteins. It has shown notable reparative and anti-inflammatory properties across diverse preclinical models. A separate study describes it as a gastric pentadecapeptide and investigated its inhibitory potential alongside two newly designed hybrid analogs, CIARA-1 and CIARA-2.
In animal studies, BPC 157 was reported to support new blood vessel formation (angiogenesis), collagen production (collagen synthesis), fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those animal studies. In a laboratory study using human arterial tissue, BPC 157 induced concentration-dependent vasorelaxation, predominantly mediated via an endothelium-dependent nitric oxide pathway.
In preclinical animal studies, BPC 157 was reported to support angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those studies. In animal studies, BPC 157 was proposed to protect skeletal muscle against ischemia-reperfusion injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity.
A review states that independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and states that it lacks an established human safety profile.
The facts do not describe BPC 157's legal status in any specific country. A review states that BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and says it lacks an established human safety profile.
A review of human clinical studies of the reviewed peptides, including BPC-157, found that such studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. The same review stated that the claimed benefits of emerging peptide supplements, including BPC-157, for musculoskeletal recovery and performance remain unsubstantiated by current human trials.
In the study, a streamlined analytical workflow was developed to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum and plasma, and BPC-157 was among the compounds detected by this workflow. Sample preparation for this workflow used a single microextraction step with 500 µL of a methanol/water (8:2, v/v) mixture, followed by detection using liquid chromatography coupled with high-resolution mass spectrometry.
Yes, in an in vitro study, BPC-157 was described as a reversible competitive acetylcholinesterase (AChE) inhibitor. The study also reported that BPC-157's hybrid analogs act the same way, with enhanced activity seen in structurally modified derivatives. Enzyme kinetics of BPC-157 and its analogs were evaluated in this in vitro work using a modified Ellman assay with Lineweaver-Burk analysis to determine the inhibition parameters.
In in vitro studies using human arteries, endothelial integrity markedly enhanced the maximal vasorelaxation produced by BPC 157. This advantage was largely abolished after NOS inhibition. In human internal mammary artery rings studied in vitro, the NOS inhibitor L-NAME increased contractile responsiveness in intact rings. L-NAME also attenuated BPC 157-induced relaxation in these intact human arterial rings.
In a rat gentamicin nephrotoxicity model, BPC 157 was applied at 10 µg/kg or 10 ng/kg, either in drinking water or daily intraperitoneally. In these rats, BPC 157 counteracted the gentamicin-increased malondialdehyde (MDA) levels in kidney tissue. BPC 157 also counteracted the gentamicin-decreased nitric oxide (NO) and superoxide dismutase (SOD) levels in kidney tissue of these rats.
According to a review, independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review concludes that BPC 157 is supported as a hypothesis-generating investigational candidate for further preclinical ischemia-reperfusion injury research rather than as an established therapy.
A review states that BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The same review states that no pharmaceutical-grade formulation of BPC-157 has been developed or validated. The review also notes that the peptide lacks BCS classification data, permeability characterization, and formal excipient compatibility studies.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.